Prediction models for biochemical failure after FS-HDR-BT 173 Supplementary A Group n Years Study specific inclusion criteria Feasibility study 30 2013-2017 Patient characteristics Age ³ 18 years; KPS ³ 70; Fit for spinal anaesthesia; IPSS < 15. Tumour characteristics Tumour location technically feasible for BT; Tumour visible on MRI and PSMA/choline-PET/CT; Biopsy proven local recurrence; PSA level £ 10.0 ng/mL; PSADT ³ 12 months; Tumour stage (MRI) £ T2c; Recurrence ³ 2 years after primary radiotherapy; No lymph node and/or distant metastases. PRECISE study 42 2018-2019 Patient characteristics See ‘Feasibility study’. Tumour characteristics Tumour location technically feasible for BT; Concordance between PSMA-PET/CT and MRI; PSA level £ 20.0 ng/mL; PSADT ³ 9 months; Tumour stage (MRI) £ T3b; Recurrence ³ 2 years after primary radiotherapy; No lymph node and/or distant metastases. Non-study 78 2015-2020 Patient characteristics See ‘Feasibility study’. Tumour characteristics No specific criteria (i.e. those not eligible for treatment within either the feasibility of the PRECISE study, for example due to higher pre-salvage PSA and/or shorter PSADT). Table S1 – Overview of inclusion criteria per study group. Legend: PSA = Prostate-specific antigen. KPS = Karnofsky performance status. IPSS = International Prostate Symptom Score. BT = Brachytherapy. PSADT = PSA-doubling time. 8
RkJQdWJsaXNoZXIy MTk4NDMw